A study to assess the Safety and Pharmacokinetics of an Inhibitor of PARP in combination with Dacarbazine
Study identifier:KU36-73
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open label, Study of the Safety and Tolerability of KU-0059436 and Dacarbazine in the Treatment of Patients With Advanced Solid Tumours
Medical condition
Melanoma neoplasms
Phase
Phase 1
Healthy volunteers
No
Study drug
KU-0059436 (AZD2281)(PARP inhibitor), dacarbazine
Sex
All
Actual Enrollment
40
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jan 2007
Primary Completion Date: 01 Jan 2009
Study Completion Date: 01 Jan 2009
Study design
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
KuDOS Pharmaceuticals Ltd (a member of the AstraZeneca Group of companies)
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 DTIC + KU-0059436 | Drug: KU-0059436 (AZD2281)(PARP inhibitor) oral Other Name: Olaparib Drug: dacarbazine intravenous injection over at least 20 minutes Other Name: DTIC |
Contacts
Investigators
Principal Investigator
Prof James Carmichael
KuDOS Pharmaceuticals Ltd
